Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus placebo for prevention of post-discharge venous thromboembolism in medically ill high-risk patients
MOH_2017-05-17_000220Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Janssen Pharmaceutical. Started Oct 2014; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2017-05-17_000220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-17_000220.